Technical Analysis for ACHN - Achillion Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
ACHN closed down 1.05 percent on Tuesday, December 12, 2017, on 76 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
|See historical ACHN trend table...|
|Date||Alert Name||Type||% Chg|
|Dec 12||New 52 Week Closing Low||Bearish||0.00%|
|Dec 12||New 52 Week Low||Other||0.00%|
|Dec 12||Wide Bands||Range Expansion||0.00%|
|Dec 12||Oversold Stochastic||Weakness||0.00%|
|Dec 11||New 52 Week Closing Low||Bearish||-1.05%|
|Dec 11||New 52 Week Low||Other||-1.05%|
|Dec 11||Outside Day||Range Expansion||-1.05%|
|Dec 11||Wide Bands||Range Expansion||-1.05%|
|Dec 11||Oversold Stochastic||Weakness||-1.05%|
|Dec 8||New 52 Week Low||Other||-2.41%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on the development of antivirals for the treatment of chronic hepatitis C viral (HCV) infection. The company's drug candidates for treating chronic HCV infection comprise Sovaprevir, a NS3 protease inhibitor, which has completed a Phase IIa clinical trial; ACH-3102, a NS5A inhibitor that is in Phase IIa clinical trial; and ACH-2684, a NS3 protease inhibitor, which has completed Phase Ia and 1b clinical trials. Its pipeline of antibacterial product candidates includes ACH-702 for the treatment of dermatologic and ophthalmic infections; and ACH-2881 for the treatment of serious resistant bacterial infections, including methicillin-resistant staphylococcus aureus. The company was founded in 1998 and is headquartered in New Haven, Connecticut.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ACHN news...
|52 Week High||5.66|
|52 Week Low||2.8|
|200-Day Moving Average||4.0968|
|50-Day Moving Average||3.7874|
|20-Day Moving Average||3.178|
|10-Day Moving Average||2.982|
|Average True Range||0.1661|
|Chandelier Exit (Long, 3 ATRs )||3.4417|
|Chandelier Exit (Short, 3 ATRs )||3.2983|
|Upper Bollinger Band||3.6661|
|Lower Bollinger Band||2.6899|
|Percent B (%b)||0.14|
|MACD Signal Line||-0.2531|
|Market Cap||387.03 Million|
|Num Shares||137 Million|
|Price-to-Earnings (P/E) Ratio||-5.66|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||3.00|
|Resistance 3 (R3)||3.00||2.96||2.97|
|Resistance 2 (R2)||2.96||2.91||2.95||2.96|
|Resistance 1 (R1)||2.89||2.89||2.87||2.89||2.95|
|Support 1 (S1)||2.78||2.80||2.76||2.78||2.71|
|Support 2 (S2)||2.74||2.78||2.73||2.70|
|Support 3 (S3)||2.67||2.74||2.69|
|Support 4 (S4)||2.67|